Refractory Convulsive Status Epilepticus in Children: Etiology, Associated Risk Factors and Outcome by BARZEGAR, Mohammad et al.
24 Iran J Child Neurol. 2015 AutumN  Vol 9 No 4
Refractory Convulsive Status Epilepticus in Children: Etiology, Associated Risk 
Factors and Outcome
1. Pediatric Neurology Department   
Pediatric  Health  Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran
2. Pediatric Cardiologist,  Pediatric 
Cardiology  ward, Sheid Rajaee 
Hospital, Iran University of Medical 
Sciences, Tehran, Iran
3. Pediatric Nephrologist, Pediatric  
Health  Research Center, Tabriz 
University of Medical Sciences, 
Tabriz, Iran
4. Pediatrician, Pediatric  Health  
Research Center, Tabriz University of 
Medical Sciences, Tabriz, Iran 
Corresponding Author
Barzegar M. MD
Pediatric Health Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran





How to Cite This Article: Barzegar M, Mahdavi M, Zalegolab behbehani A, Tabrizi A. Refractory Convulsive Status Epilepticus 
in Children: Etiology, Associated Risk Factors and Outcome. Iran J Child Neurol. Autumn 2015;9(4): 24-31.
Mohammad BARZEGAR MD1,
Mohammad MAHDAVI MD2,
Afshin GALEGOLAB BEHBEHANI MD3,




Refractory status epilepticus (RSE) is a life-threatening disease in children 
wherein the patient’s convulsive seizures do not respond to adequate initial 
anticonvulsants. RSE is associated with high rate of mortality and morbidity. 
This study was aimed to survey the risk factors leading status epilepticus (SE) to 
RSE in children, and their early outcome.
Materials & Methods
Patients with SE hospitalized in Tabriz Children’s Hospital, Iran were studied 
during the years 2007 and 2008 with regard to their clinical profile, etiology, the 
treatment methods available to them and their outcome upon release from the 
hospital.
Results
Among 132 patients with SE, 53 patients (40.15%) suffered from RSE. Acute 
symptomatic etiology was a risk factor responsible for developing RSE in 
the patient (P=0.004). Encephalitis was the most common etiology of acute 
symptomatic SE. There was no significant relationship observed between RSE 
and the patients’ age, gender, date of initial drug intake and type of seizure. The 
mortality rate was 8.3% and a new neurological deficit occurred in 25.7% of 
cases. None of RSE with encephalitis returned to the baseline status. Mortality 
and morbidity rates were significantly higher in children with RSE than in those 
with SE (P=0.006). 
Conclusion
Etiology of SE significantly influenced prognosis of it with significant incidence 
of RSE in acute symptomatic group. Because acute neurological insult such as 
encephalitis and meningitis are common causes of RSE in children, properly 
management of them is necessary to avoid permanent brain damage.
Keywords: Refractory status epilepticus; Etiology; Mortality; Morbidity; 
Children
Introduction
Status epilepticus (SE) is defined as any continuous convulsive seizure activity or 
intermittent convulsive seizure activity without regaining of consciousness between 
them lasting for more than 30 min. SE is the most common and the urgent life-
threatening neurological emergency in children (1-3). Either convulsive or no 
convulsive SE affects both children and adults; it is sometimes associated with 
high morbidity and mortality, particularly in infants varying from 4% to 39% in 
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different studies (4-6). SE is either terminated with 
anticonvulsant medications, i.e., non-refractory status 
epilepticus (NRSE) or refractory to medications, i.e., 
refractory status epilepticus (RSE), the SE that does not 
respond to initial therapy with adequate doses of two or 
three anticonvulsant medications, or status epilepticus 
lasting 60 min or longer (1, 2, 7, 8). 
The annual incidence rate of SE is 41 per 100,000 people, 
of whom approximately 9% to 44% have RSE (9-10). 
RSE is accompanied by the higher rates of morbidity and 
mortality (11), with reported the total mortality of 16% 
(12). Risk factors associated with RSE are less clearly 
known in children. Risk factors for RSE include young 
age, delay in onset of treatment and being afflicted with 
focal motor seizure (13).
The aim of the present study was to identify etiology, 
associated risk factors and outcome of RSE in SE 
pediatric patients. 
Materials &  Methods
Study population
The study group included in this study met the following 
inclusion criteria: patients younger than 18 yr of age 
admitted with a diagnosis of status epilepticus at 
Children’s Hospital, Tabriz, Iran between 2007 and 
2008. If patients experienced more than one episode 
of SE, only the first episode of SE would include in the 
study.
Study design
We did a hospital-based cross-sectional analytical study 
at Tabriz Children’s Hospital. It is a major regional 
tertiary care referral center that gives high-level 
healthcare services to the pediatric patients of north-
west of Iran, mainly East Azerbaijan Province in all 
pediatric subspecialties. All 132 consecutive patients 
presented with SE initially (Figure 1), were stabilized 
by the trained staff of the emergency room (ER) 
service with establishment of an intravenous access and 
initiation of hospital SE treatment protocol; then, were 
admitted to the Pediatric Intensive Care Unit (PICU), 
and cared for with continuous blood pressure, pulse 
oximetry and cardiac monitoring. Some patients with 
cardiorespiratory compromise (particularly RSE cases) 
were intubated and underwent mechanical ventilation. 
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Electroencephalographic (EEG) monitoring was not 
used for the diagnosis of convulsive SE initially, but 
was performed when the seizures had been controlled 
to exclude any probable diagnosis of nonconvulsive SE. 
The study was approved by Ethics Committee of Tabriz 
University of Medical Sciences and informed consent 




SE is defined as any continuous convulsive seizure 
activity or intermittent convulsive seizure activity 
without regaining of consciousness between them lasting 
for more than 30 min (1, 2).
Refractory status epilepticus
There is no single definition for RSE. Definitions used 
in the literature are different based on the number of 
used medications and the duration of the seizure activity 
(7). However, we used following definition for RSE in 
this study: the status epilepticus that does not respond 
to initial therapy with adequate doses of two or three 
anticonvulsant medications, or status epilepticus lasting 
60 min or longer despite of treatment with therapeutic 
doses of at least one first line medication, followed by 
one second line medication (1, 2, 10, 12).
Non-refractory status epilepticus
The term non-refractory status epilepticus (NRSE) was 
used to indicate those patients whose SE terminated with 
first and/or second line medications within less than 60 
min after administration of the first drug according to the 
hospital treatment protocol.
Hospital treatment protocol
There is no consensus about the optimal therapy of SE and 
RSE in the literature (14). We used modified “Medical 
College of Virginia Status Epilepticus Treatment 
protocol for Children” (15) in order to standardize the 
pediatric SE care and treatment in the emergency room 
and PICU. The treatment objective was complete control 
of patients’ clinical convulsive epileptic activity. All 
patients were treated using the following protocol:
Line1: Children who presented with convulsive seizure 
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three categories using a structured data collection 
questionnaire and related chart review as follows:
(a)Demographic data including age and gender.
(b)Clinical data including medical history, neurological 
and other physical examinations, type of seizure, 
duration of SE, different types of treatments used and 
related side effects. Classification and type of seizures 
were conducted based on the criteria of International 
League against Epilepsy (ILAE) (1).
(c)Paraclinical data including patients’ collected blood 
sample for the CBC and serum electrolytes levels such 
as sodium, calcium, phosphorus, magnesium, glucose, 
creatinine and lactate. Laboratory data recorded during 
the first 24 h after the onset of SE. In order to perform 
certain metabolic and toxicology tests, blood and urine 
samples of some patients were also collected according 
to their history, clinical examination and the initial test 
results. If meningitis or encephalitis were suspected (as 
was the case in all febrile patients), the cerebrospinal fluid 
was tapped for examinations (analysis, culture and PCR 
for herpes simplex). Presumed encephalitis was defined 
as presence of symptoms of an acute febrile illness prior 
to, or at the time of the onset of SE, with CSF pleocytosis 
and no positive findings in cerebrospinal fluid culture 
(12). 
Outcome
The patients’ outcome was evaluated during 
hospitalization and on discharge. It was categorized 
into three distinct groups based on short-term prognosis 
including mortality (death), morbidity (development of a 
new neurological deficit) and recovery (return to baseline 
condition, i.e., the same neurological condition as prior to 
RSE or NRSE) (Figure 1). Outcome considered “poor” 
if mortality and/or morbidity occurred and “good” if 
patient recovered (7).
Statistical analysis
Univariate analysis was used to determine factors 
associated with the development of RSE in patients 
presented with SE. Chi-square and Fisher’s exact tests 
were used to compare determined short-term outcome 
between RSE and NRSE groups. The t test was used 
for analysis of continuous data with normal distribution 
and Mann Whitney U test for data with non-normal 
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activity for more than 5 minutes received three repeated 
doses of 0.3 mg/kg intravenous diazepam at the 
fifteen-min intervals along with a dose of 20 mg/kg of 
intravenous phenytoin (at a rate of 1 mg/kg per min).
Line 2: If the seizures resumed or continued, they 
received intravenous phenobarbital at the dose of 20 
mg/kg during 10 to 30 minutes. If SE continued in 
children younger than 2 years 100 mg of pyridoxine was 
administered.
Line 3: If SE continued despite the first and second 
line medications, or seizures lasted 60 min or more, the 
condition was considered as the RSE and the patient 
received intravenous midazolam, a loading dose of 0.2 
mg/kg followed by a conscious infusion of 1-5 μg/kg per 
min titrated every 15 min. Treatment is typically 24 h.
Line 4: If control is still not achieved, thiopental sodium 
with an initial intravenous loading dose 5 mg/kg and 
maintenance dose of 1-5 mg/kg/h in PICU is necessary.
Etiology
SE was classified into 4 categories based on previously 
published studies (16-19) as follows:
(a)Acute symptomatic: SE develops because of acute 
neurological insults such as trauma, CNS infection, 
metabolic disturbances or a systematic disorder.
(b)Remote symptomatic: This category includes 
patients with a particular neurological disorder (chronic 
encephalopaties) predisposing them to epileptic seizures; 
and this includes cases due to previous congenital or 
acquired epileptogenic brain damage. Some investigators 
separate a category of progressive encephalopaties that 
others include them with remote symptomatic (18).
(c)Idiopathic: The idiopathic category, which sometimes 
is also termed cryptogenic, includes epileptic patients 
who have SE because of their sudden discontinuation 
of anticonvulsant medication or in the absence of an 
underlying lesion in the central nervous system or any 
causal brain damage.
(d)Febrile: The febrile SE includes epileptic seizures 
accompanied by fever lasting more than 30 min while 
cerebrospinal fluid analysis does not indicate anything 
in favor of CNS infection.
Demographic, clinical and paraclinical data
The patients’ data was collected and documented in 
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P=0.006). None of RSE with encephalitis returned to 
the baseline status. Dividing the patients’ outcome into 
the two categories of good and poor (poor outcome 
means death or development of a new neurological 
deficit) indicated that there was a significant relationship 
between the patients’ outcome and their etiology. In 
overall, poor outcome was more prevalent in the acute 
symptomatic etiology in SE patients (P=0.04). There was 
no significant relationship between a poor outcome and 
the patients’ age, gender and initiation of anticonvulsant 
medications. 
Discussion
Convulsive SE is the most common form of SE and 
accounts for about 90% of all pediatric SE cases 
(4). In the present study, RSE occurred in 40.15% 
of patients with convulsive SE. In a study of 193 
pediatric SE patients, 26% had RSE (16). Different 
studies have reported the prevalence of RSE among 
SE patients from 11% to 43% (4, 8-12, 20-22). The 
differences among different studies can be attributed 
to sociological, economical and geographical diversity 
of the study populations and the referral bias existing 
in their selection and the lack of a standard definition 
for RSE. Tabriz Children’s Hospital is a tertiary -level 
referral center and almost all children with critical 
conditions (such as SE) referred to this center solely.
An acute symptomatic etiology was the most prevalent 
cause of RSE (41.51%), and SE due to an acute 
symptomatic etiology increased the risk of RSE by 
3.35 times. In various studies, an acute symptomatic 
etiology was proved the major associated risk factor 
for RSE in SE patients. In a study on 22 children with 
RSE, an acute symptomatic etiology was presented 
as a risk factor for RSE and mortality was related to 
etiology and EEG finding (12). In a review article on 
outcome and mortality of SE in children, adolescents 
and adults, sequel and risk of recurrence of SE were 
primarily related to the underlying cause; RSE was most 
often consequence of an acute neurologic condition or 
neurodegenerative disease (2). 
In the present study, the type of epileptic seizure was 
not revealed as a associated risk factor for RSE, but 
in several studies, the focal seizure at the onset of the 
epileptic seizure was considered a risk factor related to 
distribution. Statistical analysis was performed using 
SPSS 17.0 (Chicago, IL, USA). Differences were 
considered significant at P<0.05.
Results
Age, gender and patients
There were 73 (55.30%) boys and 59 (44.70%) girls 
presented with SE to the hospital. From132 patients, 79 
(59.85%) had NRSE and 53 (40.15%) had RSE, with 
the mean age 38.44±0.61 months (ranging from 2 to 204 
months) for NRSE group and 40.11±0.78 months (ranging 
from 1 – 156 months) for RSE group, respectively 
(P=0.82). With regard to the gender, 46 (58.22%) in 
NRSE group and 27 (50.94%) in RSE group were 
boys (P=0.28). The time interval between the initiation 
of seizure and the administration of anticonvulsant 
medications was 20.83±17.48 min (ranging from 3 to 
75 min) in NRSE group and 15.02±13.56 min (ranging 
from 2 to 45 min) in RSE group (P=0.15). 
Etiology
Table 1 compares the etiologic factors associated with 
the two groups of patients. 
There was a rather significant etiologic variation between 
the two groups. Acute symptomatic etiology was an 
associated risk factor with RSE (OR=3.35; 95% CI 1.47-
7.61, P=0.001). Febrile seizure was against development 
of RSE (P=0.001).  The etiologies of acute and remote 
symptomatic SE are shown in Table 2.
Hospital treatment protocol
All 53 patients with RSE received anticonvulsants, i.e. 
diazepam, phenytoin and phenobarbital, and midazolam 
infusion as well. In 42 (79.24%) patients, SE resumed 
and in 11 (20.76%) thiopental infused since they did not 
respond to the midazolam. 
Outcome
Regarding the patients’ short-term outcome, there were 
11 (8.33%) deaths, 9 and 2 of them were from the RSE and 
SE groups, respectively (OR=7.34; 95%CI: 1.52-35/46; 
P=0.008). The risk of death was 7 times higher in the 
RSE group compared to SE group. A new neurological 
deficit occurred in 21 (38.18%) RSE patients and in 
13 (16.88%) SE patients (OR=3.04; 95%CI:1.36-6.82; 
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RSE (20, 22). 
 Similar to other studies, no significant relationship was 
found between the occurrence of RSE in children and 
their age and gender (2, 4, 13, 19, 21-22); however, some 
studies indicate that age is an associated risk factor for 
RSE (6,  23). 
Like other studies, we did not observe a significant 
relationship between the initiation of anticonvulsant 
medications and occurrence of RSE; however, one study 
indicated a correlation between delay in the start of 
treatment and transformation of SE to RSE (8).
  The main risk factor related to RSE is acute symptomatic 
etiology, which leads to structural-functional damage and 
the inability to respond to anticonvulsant medications. 
Although efforts are made to control seizures, it is vital 
that the therapy is directed to the underlying condition 
whenever possible. Indeed, when it is not done, there 
will be a significant risk for prolongation of the SE and 
rendering it harder to control (8-12). 
 According to the present study, midazolam infusion 
terminated epileptic seizures in 43 (78.19%) of patients 
with RSE. The rate of midazolam success in controlling 
seizure varied from 73% to 95% (20, 24-25). In a 
comparative study between thiopental, midazolam and 
propofol for controlling RSE, the rate of success was 
the same for all three medications; nevertheless, rate 
of recurrence was higher in midazolam group even 
though they suffered less systematic side effects (26). 
The management of refractory status epilepticus is 
heterogeneous in many aspects, even among clinicians 
who are most familiar with this severe condition (27). 
It appears that under conditions where a favorable 
PICU is lacking and by considering costs of treatment, 
midazolam is the least costly drug for refractory 
generalized convulsive SE in children (29). 
In the present study, 45 (34.09%) of patients suffered from 
the poor outcome (death and a new neurologic deficit) 
that was significantly higher in the RSE group compared 
to NRSE group; this result was similar to that obtained 
by several studies in which there was a systematic 
relationship between SE patients’ neurological outcome 
and their etiology (4, 12, 16, 22).
In a study of 122 children with SE, no death was directly 
attributable to generalized convulsive SE (29). Therefore, 
in order to decrease mortality and morbidity rates, 
controlling the SE is not the only contributing factor; 
rather, the early and proper diagnosis of the underlying 
acute disease greatly contributes to improving the 
patients’ outcome. 
 In our study, none of RSE due to encephalitis returned to 
the baseline condition. In a study of 46 children with SE 
secondary to presumed encephalitis, 20 were diagnosed 
with RSE, 6 were died and 13 developed a new 
neurologic deficit. In the follow-up examinations, none 
of the patients recovered to their previous neurological 
conditions (30). 
A limitation of this study was that due to unavailability 
of EEG monitoring facility we did not use this valuable 
instrument for detecting subclinical seizure and 
detecting burst suppression pattern for evaluating effect 
of thiopental infusion.
In conclusion, Etiology of SE significantly influenced 
prognosis of it with significant incidence of RSE in acute 
symptomatic group. Because acute neurological insult 
such as encephalitis and meningitis are common causes 
of RSE in children, properly management of them is 
necessary to avoid permanent brain damage.  
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Table 1. Etiological Factors Associated with SE and RSE
Groups
Etiology
RSE NRSE P. value
Febrile 6 (11.32) 34 (43.4) 0.001
Acute Symptomatic 22 (41.51) 12 (15.19) 0.001
Remote Symptomatic 20 (37.73) 22 (27.84) 0.27
Idiopathic 5 (9.43) 11 (13.92) 0.28
NRSE: non refractory status epilepticus; RSE: refractory status epilepticus
Table 2: Etiologies of 76 cases with acute or remote symptomatic status epilepticus examined in this study
1. Acute symptomatic (34) 2. Remote symptomatic (42)
Encephalitis 14
Cerebral palsy,
Global developmental delay and
Mental retardation
24
Meningitis 5 Hydrocephaly 1
Hyponatermia 4 Anjelman syndrome 1
Hypernatremia 1 Rett syndrome 1
Intracranial hemorrhage 3 Sturge-weber 2
Drug induced 3 Tuberosis sclerosis 1
Cerebral infarction 1 Suspected Alper disease 1
Hypoglycemia 2 Organic aciduria 1
Hypoxic –ischemic enceph induced 1 Brain malformation 8
Brain Tumor 2
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